I am a scientist and entrepreneur with 17 years of experience in drug development, computational techniques, and artificial intelligence. Throughout my career, I have contributed to groundbreaking drug discovery programs through global academic-industry partnerships.Some of my key achievements include:》Advancing the field of anticancer drug design by introducing enzymatic bioconversion combined with multistep organic synthesis to create potent natural product analogs (CNRS & Laboratoires Pierre Fabre, France).》Discovering promising kinase and P-glycoprotein inhibitors through bioassay-guided fractionation and molecular docking, advancing treatments for cancer and neurodegenerative disorders (University of Queensland, Australia, in collaboration with Noscira, Spain).》Designing potent GPCR peptide ligands for type 2 diabetes and acute myeloid leukemia in collaboration with Pfizer (USA) and Protagonist Therapeutics (Australia).》Developing cutting-edge machine learning models for natural product drug discovery and peptide drug design to address infectious diseases in humans, livestock, and crops (Mexico).Through 𝘐𝘯𝘨𝘦𝘯𝘪𝘦 𝘉𝘪𝘰, I am building a platform to integrate AI-driven tools with biomolecular innovation, empowering academic and industrial partners to solve complex research challenges. I am committed to driving innovation through PTNG Scientific offering strategic consulting services via tailored contracts and partnerships. As I expand this initiative, I remain open to R&D leadership roles in academic institutions, biotechnology startups, and pharmaceutical companies, where I can leverage my experience in collaborative, interdisciplinary environments to support the Australian bio-economy and beyond.